|
1
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Nashimoto A, Akazawa K, Isobe Y, et al:
Gastric cancer treated in 2002 in Japan: 2009 annual report of the
JGCA nationwide registry. Gastric Cancer. 16:1–27. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunningham D, Starling N, Rao S, et al:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weinstein IB and Joe AK: Mechanisms of
disease: Oncogene addiction - a rationale for molecular targeting
in cancer therapy. Nat Clin Pract Oncol. 3:448–457. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gravalos C and Jimeno A: HER2 in gastric
cancer: a new prognostic factor and a novel therapeutic target. Ann
Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al; ToGA Trial Investigators. Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar
|
|
9
|
Bang YJ: A randomized, open-label, phase
III study of lapatinib in combination with weekly paclitaxel versus
weekly paclitaxel alone in the second-line treatment of HER2
amplified advanced gastric cancer (AGC) in Asian population: Tytan
study. J Clin Oncol. 30(Suppl 34): abstract 11. 2012.
|
|
10
|
Hecht JR, Bang YJ, Qin S, et al: Lapatinib
in combination with capecitabine plus oxaliplatin (CapeOx) in
HER2-positive advanced or metastatic gastric, esophageal, or
gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J
Clin Oncol. 31(Suppl): abstract LBA4001. 2013.
|
|
11
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signaling network: receptor heterodimerization in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rubin I and Yarden Y: The basic biology of
HER2. Ann Oncol. 12(Suppl 1): S3–S8. 2001. View Article : Google Scholar
|
|
13
|
Cuello M, Ettenberg SA, Clark AS, et al:
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin)
enhances tumor necrosis factor-related apoptosis-inducing
ligand-mediated apoptosis in breast and ovarian cancer cell lines
that overexpress erbB-2. Cancer Res. 61:4892–4900. 2001.
|
|
14
|
Spector NL and Blackwell KL: Understanding
the mechanisms behind trastuzumab therapy for human epidermal
growth factor receptor 2-positive breast cancer. J Clin Oncol.
27:5838–5847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barok M, Isola J, Palyi-Krekk Z, et al:
Trastuzumab causes antibody-dependent cellular
cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1
breast cancer xenografts despite intrinsic drug resistance. Mol
Cancer Ther. 6:2065–2072. 2007. View Article : Google Scholar
|
|
16
|
Molina MA, Codony-Servat J, Albanell J, et
al: Trastuzumab (herceptin), a humanized anti-Her2 receptor
monoclonal antibody, inhibits basal and activated Her2 ectodomain
cleavage in breast cancer cells. Cancer Res. 61:4744–4749.
2001.
|
|
17
|
Saez R, Molina MA, Ramsey EE, et al:
p95HER-2 predicts worse outcome in patients with HER-2-positive
breast cancer. Clin Cancer Res. 12:424–431. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Izumi Y, Xu L, di Tomaso E, Fukumura D and
Jain RK: Tumour biology: herceptin acts as an anti-angiogenic
cocktail. Nature. 416:279–280. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vogel CL, Cobleigh MA, Tripathy D, et al:
Efficacy and safety of trastuzumab as a single agent in first-line
treatment of HER2-overexpressing metastatic breast cancer. J Clin
Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cobleigh MA, Vogel CL, Tripathy D, et al:
Multinational study of the efficacy and safety of humanized
anti-HER2 monoclonal antibody in women who have HER2-overexpressing
metastatic breast cancer that has progressed after chemotherapy for
metastatic disease. J Clin Oncol. 17:2639–2648. 1999.
|
|
21
|
Kelley JR and Duggan JM: Gastric cancer
epidemiology and risk factors. J Clin Epidemiol. 56:1–9. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blackwell KL, Burstein HJ, Storniolo AM,
et al: Overall survival benefit with lapatinib in combination with
trastuzumab for patients with human epidermal growth factor
receptor 2-positive metastatic breast cancer: final results from
the EGF104900 study. J Clin Oncol. 30:2585–2592. 2012. View Article : Google Scholar
|
|
23
|
Scaltriti M, Rojo F, Ocana A, et al:
Expression of p95HER2, a truncated form of the HER2 receptor, and
response to anti-HER2 therapies in breast cancer. J Natl Cancer
Inst. 99:628–638. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amir E, Ocana A, Seruga B, Freedman O and
Clemons M: Lapatinib and HER2 status: results of a meta-analysis of
randomized phase III trials in metastatic breast cancer. Cancer
Treat Rev. 36:410–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim JW, Kim HP, Im SA, et al: The growth
inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2
tyrosine kinase, in gastric cancer cell lines. Cancer Lett.
272:296–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wainberg ZA, Anghel A, Desai AJ, et al:
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively
inhibits HER2-amplified human gastric cancer cells and is
synergistic with trastuzumab in vitro and in vivo.
Clin Cancer Res. 16:1509–1519. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim HP, Yoon YK, Kim JW, et al: Lapatinib,
a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates
thymidylate synthase by inhibiting the nuclear translocation of
EGFR and HER2. PLoS One. 4:e59332009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iqbal S, Goldman B, Fenoglio-Preiser CM,
et al: Southwest Oncology Group study S0413: a phase II trial of
lapatinib (GW572016) as first-line therapy in patients with
advanced or metastatic gastric cancer. Ann Oncol. 22:2610–2615.
2011. View Article : Google Scholar
|
|
29
|
Akiyama T, Sudo C, Ogawara H, Toyoshima K
and Yamamoto T: The product of the human c-erbB-2 gene: a
185-kilodalton glycoprotein with tyrosine kinase activity. Science.
232:1644–1646. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Di Fiore PP, Pierce JH, Kraus MH, et al:
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
Science. 237:178–182. 1987.
|
|
31
|
Graus-Porta D, Beerli RR, Daly JM and
Hynes NE: ErbB-2, the preferred heterodimerization partner of all
ErbB receptors, is a mediator of lateral signaling. EMBO J.
16:1647–1655. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cho HS, Mason K, Ramyar KX, et al:
Structure of the extracellular region of HER2 alone and in complex
with the Herceptin Fab. Nature. 421:756–760. 2003. View Article : Google Scholar
|
|
33
|
Garrett TP, McKern NM, Lou M, et al: The
crystal structure of a truncated ErbB2 ectodomain reveals an active
conformation, poised to interact with other ErbB receptors. Mol
Cell. 11:495–505. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wong H and Yau T: Targeted therapy in the
management of advanced gastric cancer: are we making progress in
the era of personalized medicine? Oncologist. 17:346–358. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baselga J and Swain SM: Novel anticancer
targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ocana A, Vera-Badillo F, Seruga B, et al:
HER3 overexpression and survival in solid tumors: a meta-analysis.
J Natl Cancer Inst. 105:266–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hayashi M, Inokuchi M, Takagi Y, et al:
High expression of HER3 is associated with a decreased survival in
gastric cancer. Clin Cancer Res. 14:7843–7849. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Begnami MD, Fukuda E, Fregnani JH, et al:
Prognostic implications of altered human epidermal growth factor
receptors (HERs) in gastric carcinomas: HER2 and HER3 are
predictors of poor outcome. J Clin Oncol. 29:3030–3036. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang XL, Yang YS, Xu DP, et al:
Comparative study on overexpression of HER2/neu and HER3 in gastric
cancer. World J Surg. 33:2112–2118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sakai K, Yokote H, Murakami-Murofushi K,
Tamura T, Saijo N and Nishio K: Pertuzumab, a novel HER
dimerization inhibitor, inhibits the growth of human lung cancer
cells mediated by the HER3 signaling pathway. Cancer Sci.
98:1498–1503. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee-Hoeflich ST, Crocker L, Yao E, Pham T,
Munroe X, Hoeflich KP, Sliwkowski MX and Stern HM: A central role
for HER3 in HER2-amplified breast cancer: implications for targeted
therapy. Cancer Res. 68:5878–5887. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Baselga J, Cortes J, Kim SB, et al:
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast
cancer. N Engl J Med. 366:109–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Swain SM, Kim SB, Cortes J, et al:
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic
breast cancer (CLEOPATRA study): overall survival results from a
randomised, double-blind, placebo-controlled, phase 3 study. Lancet
Oncol. 14:461–471. 2013. View Article : Google Scholar
|
|
45
|
Yamashita-Kashima Y, Iijima S, Yorozu K,
Furugaki K, Kurasawa M, Ohta M and Fujimoto-Ouchi K: Pertuzumab in
combination with trastuzumab shows significantly enhanced antitumor
activity in HER2-positive human gastric cancer xenograft models.
Clin Cancer Res. 17:5060–5070. 2011. View Article : Google Scholar
|
|
46
|
Berger MB, Mendrola JM and Lemmon MA:
ErbB3/HER3 does not homodimerize upon neuregulin binding at the
cell surface. FEBS Lett. 569:332–336. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schulze WX, Deng L and Mann M:
Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol
Syst Biol. 1:2005.00082005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hsieh AC and Moasser MM: Targeting HER
proteins in cancer therapy and the role of the non-target HER3. Br
J Cancer. 97:453–457. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Narayan M, Wilken JA, Harris LN, Baron AT,
Kimbler KD and Maihle NJ: Trastuzumab-induced HER reprogramming in
‘resistant’ breast carcinoma cells. Cancer Res. 69:2191–2194.
2009.PubMed/NCBI
|
|
50
|
Holbro T, Beerli RR, Maurer F, Koziczak M,
Barbas CF III and Hynes NE: The ErbB2/ErbB3 heterodimer functions
as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor
cell proliferation. Proc Natl Acad Sci USA. 100:8933–8938. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Garrett JT, Olivares MG, Rinehart C, et
al: Transcriptional and posttranslational up-regulation of HER3
(ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
Proc Natl Acad Sci USA. 108:5021–5026. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sergina NV, Rausch M, Wang D, Blair J,
Hann B, Shokat KM and Moasser MM: Escape from HER-family tyrosine
kinase inhibitor therapy by the kinase-inactive HER3. Nature.
445:437–441. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nam HJ, Ching KA, Kan J, et al: Evaluation
of the antitumor effects and mechanisms of PF00299804, a pan-HER
inhibitor, alone or in combination with chemotherapy or targeted
agents in gastric cancer. Mol Cancer Ther. 11:439–451. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Khoury H, Naujokas MA, Zuo D, et al: HGF
converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol
Biol Cell. 16:550–561. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lai AZ, Abella JV and Park M: Crosstalk in
Met receptor oncogenesis. Trends Cell Biol. 19:542–551. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Puri N and Salgia R: Synergism of EGFR and
c-Met pathways, cross-talk and inhibition, in non-small cell lung
cancer. J Carcinog. 7:92008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Trusolino L, Bertotti A and Comoglio PM:
MET signalling: principles and functions in development, organ
regeneration and cancer. Nat Rev Mol Cell Biol. 11:834–848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Liska D, Chen CT, Bachleitner-Hofmann T,
Christensen JG and Weiser MR: HGF rescues colorectal cancer cells
from EGFR inhibition via MET activation. Clin Cancer Res.
17:472–482. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Shattuck DL, Miller JK, Carraway KL III
and Sweeney C: Met receptor contributes to trastuzumab resistance
of Her2-overexpressing breast cancer cells. Cancer Res.
68:1471–1477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nakajima M, Sawada H, Yamada Y, et al: The
prognostic significance of amplification and overexpression of
c-met and c-erb B-2 in human gastric carcinomas. Cancer.
85:1894–1902. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kuniyasu H, Yasui W, Kitadai Y, Yokozaki
H, Ito H and Tahara E: Frequent amplification of the c-met gene in
scirrhous type stomach cancer. Biochem Biophys Res Commun.
189:227–232. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Janjigian YY, Tang LH, Coit DG, et al: MET
expression and amplification in patients with localized gastric
cancer. Cancer Epidemiol Biomarkers Prev. 20:1021–1027. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen CT, Kim H, Liska D, Gao S,
Christensen JG and Weiser MR: MET activation mediates resistance to
lapatinib inhibition of HER2-amplified gastric cancer cells. Mol
Cancer Ther. 11:660–669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Guo A, Villén J, Kornhauser J, et al:
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl
Acad Sci USA. 105:692–697. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Bachleitner-Hofmann T, Sun MY, Chen CT, et
al: HER kinase activation confers resistance to MET tyrosine kinase
inhibition in MET oncogene-addicted gastric cancer cells. Mol
Cancer Ther. 7:3499–3508. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Corso S, Ghiso E, Cepero V, et al:
Activation of HER family members in gastric carcinoma cells
mediates resistance to MET inhibition. Mol Cancer. 9:1212010.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Nagata Y, Lan KH, Zhou X, et al: PTEN
activation contributes to tumor inhibition by trastuzumab, and loss
of PTEN predicts trastuzumab resistance in patients. Cancer Cell.
6:117–127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Fujita T, Doihara H, Kawasaki K, et al:
PTEN activity could be a predictive marker of trastuzumab efficacy
in the treatment of ErbB2-overexpressing breast cancer. Br J
Cancer. 94:247–252. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Isakoff SJ, Engelman JA, Irie HY, et al:
Breast cancer-associated PIK3CA mutations are oncogenic in mammary
epithelial cells. Cancer Res. 65:10992–11000. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Samuels Y, Diaz LA Jr, Schmidt-Kittler O,
et al: Mutant PIK3CA promotes cell growth and invasion of human
cancer cells. Cancer Cell. 7:561–573. 2005. View Article : Google Scholar
|
|
72
|
She QB, Chandarlapaty S, Ye Q, et al:
Breast tumor cells with PI3K mutation or HER2 amplification are
selectively addicted to Akt signaling. PLoS One. 3:e30652008.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Berns K, Horlings HM, Hennessy BT, et al:
A functional genetic approach identifies the PI3K pathway as a
major determinant of trastuzumab resistance in breast cancer.
Cancer Cell. 12:395–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Byun DS, Cho K, Ryu BK, et al: Frequent
monoallelic deletion of PTEN and its reciprocal association with
PIK3CA amplification in gastric carcinoma. Int J Cancer.
104:318–327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Oki E, Kakeji Y, Baba H, et al: Impact of
loss of heterozygosity of encoding phosphate and tensin homolog on
the prognosis of gastric cancer. J Gastroenterol Hepatol.
21:814–818. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li YL, Tian Z, Wu DY, Fu BY and Xin Y:
Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor
gene PTEN in gastric cancer and precancerous lesions. World J
Gastroenterol. 11:285–288. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Esteva FJ, Guo H, Zhang S, et al: PTEN,
PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab
response and survival in patients with HER2-positive metastatic
breast cancer. Am J Pathol. 177:1647–1656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Chen X, Zhu Q, Zhu L, et al: Clinical
perspective of afatinib in non-small cell lung cancer. Lung Cancer.
81:155–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Garner A, Sheng Q, Bialucha U, et al:
LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG
driven tumor growth by trapping HER3 in the inactive conformation.
Cancer Res. 72(Suppl 8): abstract 2733. 2012. View Article : Google Scholar
|
|
80
|
Hirai H, Sootome H, Nakatsuru Y, et al:
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy
by standard chemotherapeutic agents or molecular targeted drugs in
vitro and in vivo. Mol Cancer Ther. 9:1956–1967. 2010. View Article : Google Scholar
|
|
81
|
McDonagh CF, Huhalov A, Harms BD, et al:
Antitumor activity of a novel bispecific antibody that targets the
ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced
activation of ErbB3. Mol Cancer Ther. 11:582–593. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Berardi R, Santoni M, Morgese F, et al:
Novel small molecule EGFR inhibitors as candidate drugs in
non–small cell lung cancer. Onco Targets Ther. 6:563–576. 2013.
|
